These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 30477319)

  • 1. Patterns of treatment with antiplatelet therapy after an acute coronary syndrome: Data from a large database in a community setting.
    Cimminiello C; Dondi L; Pedrini A; Ronconi G; Calabria S; Piccinni C; Polo Friz H; Martini N; Maggioni AP
    Eur J Prev Cardiol; 2019 May; 26(8):836-846. PubMed ID: 30477319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of antiplatelet agents after an acute coronary syndrome in a large community Italian setting of more than 12 million subjects.
    Maggioni AP; Dondi L; Pedrini A; Ronconi G; Calabria S; Cimminiello C; Martini N
    Eur Heart J Acute Cardiovasc Care; 2019 Sep; 8(6):527-535. PubMed ID: 30209955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment pattern of contemporary dual antiplatelet therapies after acute coronary syndrome: a Swedish nationwide population-based cohort study.
    Angerås O; Hasvold P; Thuresson M; Deleskog A; ÖBraun O
    Scand Cardiovasc J; 2016; 50(2):99-107. PubMed ID: 26564402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The causes and outcomes of inadequate implementation of existing guidelines for antiplatelet treatment in patients with acute coronary syndrome: the experience from Taiwan Acute Coronary Syndrome Descriptive Registry (T-ACCORD Registry).
    Cheng CI; Chen CP; Kuan PL; Lei MH; Liau CS; Ueng KC; Wu CJ; Lai WT
    Clin Cardiol; 2010 Jun; 33(6):E40-8. PubMed ID: 20552592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are We Optimizing the Use of Dual Antiplatelet Therapy in Patients Hospitalized with Acute Myocardial Infarction?
    Hariri E; Lessard D; Gore J; Rade J; Goldberg R
    Cardiovasc Revasc Med; 2020 Feb; 21(2):182-188. PubMed ID: 31129036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes, health costs and use of antiplatelet agents in 7,082 patients admitted for an acute coronary syndrome occurring in a large community setting.
    Maggioni AP; Rossi E; Cinconze E; Roggeri DP; Roggeri A; Fabbri G; De Rosa M;
    Cardiovasc Drugs Ther; 2013 Aug; 27(4):333-40. PubMed ID: 23519685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After Percutaneous Coronary Intervention, 2008-2016.
    Dayoub EJ; Seigerman M; Tuteja S; Kobayashi T; Kolansky DM; Giri J; Groeneveld PW
    JAMA Intern Med; 2018 Jul; 178(7):943-950. PubMed ID: 29799992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statin Utilization Patterns and Outcomes for Patients with Acute Coronary Syndrome During and Following Inpatient Admissions.
    Boklage SH; Malangone-Monaco E; Lopez-Gonzalez L; Ding Y; Henriques C; Elassal J
    Cardiovasc Drugs Ther; 2018 Jun; 32(3):273-280. PubMed ID: 29855748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry.
    Basra SS; Wang TY; Simon DN; Chiswell K; Virani SS; Alam M; Nambi V; Denktas AE; Deswal A; Bozkurt B; Ballantyne CM; Peterson ED; Jneid H
    J Am Heart Assoc; 2018 Jun; 7(12):. PubMed ID: 29886424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of dyspnea on medical utilization and affiliated costs in patients with acute coronary syndrome.
    Bonafede M; Jing Y; Gdovin Bergeson J; Liffmann D; Makenbaeva D; Graham J; Deitelzweig SB
    Hosp Pract (1995); 2011 Aug; 39(3):16-22. PubMed ID: 21881388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world clopidogrel utilization in acute coronary syndromes: patients selection and outcomes in a single-center experience.
    Castini D; Persampieri S; Cazzaniga S; Ferrante G; Centola M; Lucreziotti S; Salerno-Uriarte D; Sponzilli C; Carugo S
    Ther Adv Cardiovasc Dis; 2017 Dec; 11(12):323-331. PubMed ID: 29134853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in cardiovascular and bleeding outcomes in acute coronary syndrome patients treated with or without proton-pump inhibitors during the introduction of novel P2Y12 inhibitors: a five-year experience from a single-centre observational registry.
    Hoedemaker NPG; Damman P; Ottervanger JP; Dambrink JHE; Gosselink ATM; Kedhi E; Kolkman E; de Winter RJ; van 't Hof AWJ
    Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):127-138. PubMed ID: 30084902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discharge Prescription Patterns for Antiplatelet Therapy Following Lower Extremity Peripheral Vascular Intervention.
    Singh N; Ding L; Magee GA; Shavelle DM; Kashyap VS; Garg PK
    Circ Cardiovasc Interv; 2020 Aug; 13(8):e008791. PubMed ID: 32791948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients.
    Straub N; Beivers A; Lenk E; Aradi D; Sibbing D
    Thromb Haemost; 2014 Feb; 111(2):290-9. PubMed ID: 24154566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term antithrombotic management patterns in Asian patients with acute coronary syndrome: 2-year observations from the EPICOR Asia study.
    Zheng B; Huo Y; Lee SW; Sawhney JPS; Kim HS; Krittayaphong R; Pocock SJ; Nhan VT; Alonso Garcia A; Chin CT; Jiang J; Jan S; Vega AM; Hayashi N; Ong TK
    Clin Cardiol; 2020 Sep; 43(9):999-1008. PubMed ID: 32618009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome.
    Coleman CI; Limone BL
    Am J Cardiol; 2013 Aug; 112(3):355-62. PubMed ID: 23631863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temporal Trends in the Use of Antiplatelet Therapy in Patients With Acute Coronary Syndromes.
    Esteve-Pastor MA; Ruíz-Nodar JM; Orenes-Piñero E; Rivera-Caravaca JM; Quintana-Giner M; Véliz-Martínez A; Tello-Montoliu A; PerniasEscrig V; Sandín Rollán M; Vicente-Ibarra N; MacíasVillanego MJ; Candela Sánchez E; Carrillo Alemán L; Lozano T; Valdés M; Marín F
    J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):57-65. PubMed ID: 28789568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes, health resource use, and cost in patients with early versus late dual or triple anti-platelet treatment for acute coronary syndrome.
    Friedman H; Mollon P; Lian J; Navaratnam P
    Am J Cardiovasc Drugs; 2013 Aug; 13(4):273-83. PubMed ID: 23728829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ticagrelor for acute coronary syndrome?
    Drug Ther Bull; 2011 Jun; 49(6):66-8. PubMed ID: 21632607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Real-World" Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States.
    Larmore C; Effron MB; Molife C; DeKoven M; Zhu Y; Lu J; Karkare S; Lieu HD; Lee WC; Vetrovec GW
    Catheter Cardiovasc Interv; 2016 Oct; 88(4):535-544. PubMed ID: 26577386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.